Unknown PHASE2 INTERVENTIONAL NCT00285597

Ursodeoxycholic Acid in Chronic Heart Failure

Ursodeoxycholic Acid Therapy in Chronic Heart Failure: A Placebo-controlled Study Evaluating the Effects of Ursodeoxycholic Acid on Peripheral Blood Flow and Immune Function

Sponsor: Dr. Falk Pharma GmbH

Conditions Heart Failure, Congestive

Interventions Ursodeoxycholic Acid

Updated 5 times since 2017 Last updated: Oct 8, 2009 Started: May 31, 2004 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Heart Failure, Congestive and is currently ongoing. Dr. Falk Pharma GmbH leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Falk Pharma GmbH
National Heart and Lung Institute

Data source: National Heart and Lung Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom